Cargando…

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization

Objective: In this work we monitored both total and IgG anti-SARS-CoV-2 antibodies responses after BNT162b2 vaccine booster immunization in a cohort of ostensibly healthy healthcare workers. Methods: The study population consisted of 266 subjects (median age, 46 years and interquartile range (IQR),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvagno, Gian Luca, Lippi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227877/ https://www.ncbi.nlm.nih.gov/pubmed/35746499 http://dx.doi.org/10.3390/vaccines10060890

Ejemplares similares

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

The Comparability of Anti-SARS-CoV-2 IgG Levels Measured with Different Immunoassays Varies over Time after Primary BNT162b2 Vaccination and Homologous Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
por: Salvagno, G.L., et al.
Publicado: (2022)

Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
por: Danese, Elisa, et al.
Publicado: (2021)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
por: Lau, Chin Shern, et al.
Publicado: (2022)

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
por: Giossi, Riccardo, et al.
Publicado: (2022)

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
por: Lau, Chin Shern, et al.
Publicado: (2022)

Impacto de la vacunación primaria con BNT162b2 y una dosis de refuerzo homóloga en los anticuerpos IgA contra SARS-CoV-2 en profesionales sanitarios seronegativos
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?
por: Takeuchi, Masaaki, et al.
Publicado: (2022)

Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers
por: Renna, Laura V., et al.
Publicado: (2023)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?
por: Takeuchi, Masaaki, et al.
Publicado: (2021)

Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273
por: Ailsworth, Samuel M., et al.
Publicado: (2023)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients
por: Hamaya, Tomoko, et al.
Publicado: (2022)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
por: Hickey, Thomas E., et al.
Publicado: (2023)

IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination
por: Van Elslande, Jan, et al.
Publicado: (2022)

The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters
por: Golec, Marlena, et al.
Publicado: (2022)

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy
por: Cosan, Fulya, et al.
Publicado: (2023)

Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer
por: Schwedler, Christian, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
por: Rechavi, Yoav, et al.
Publicado: (2021)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_etr3md57e1vfl43i9ge35khtku